Loading clinical trials...
Loading clinical trials...
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Interventions
AMG 176
Azacitidine
+1 more
Locations
24
United States
City of Hope National Medical Center
Duarte, California, United States
University of California Davis Medical Center
Sacramento, California, United States
University of Colorado
Aurora, Colorado, United States
Northside Hospital
Atlanta, Georgia, United States
University of Chicago Hospital
Chicago, Illinois, United States
University Medical Center New Orleans
New Orleans, Louisiana, United States
Start Date
June 13, 2016
Primary Completion Date
May 27, 2024
Completion Date
May 27, 2024
Last Updated
July 9, 2025
NCT07138209
NCT06660368
NCT05913804
NCT02074839
NCT06961669
NCT05241093
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions